演題詳細

ポスター / Poster

ポスター 20 (Poster 20) :Mantle Cell Lymphoma

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
三浦 勝浩 (Katsuhiro Miura):1
1:日本大学 血液膠原病内科
 
前へ戻る

Analysis of outcomes of patients with mantle cell lymphoma post rituximab era

演題番号 : PS-1-143

塩田 祐子 (Yuko Shiota):1、土橋 史明 (Nobuaki Dobashi):1、武井 豊 (Yutaka Takei):1、大場 理恵 (Rie Ohba):1、南 次郎 (Jiro Minami):1、小笠原 洋治 (Yoji Ogasawara):2、横山 洋紀 (Hiroki Yokoyama):2、町島 智人 (Tomohito Machishima):2、溝呂木 ふみ (Fumi Mizorogi):1、薄井 紀子 (Noriko Usui):1、相羽 惠介 (Keisuke Aiba):2

1:Div. Oncology/Hematology, Jikei University Daisan hospital, Tokyo, Japan、2:Div. Oncology/Hematology, Jikei University School of Medicine, Tokyo, Japan

 

[Background] Mantle cell lymphoma (MCL) is generally considered to be aggressive and incurable, but it has a heterogeneous clinical course and there certainly exists an indolent subgroup. [Patients & Methods] We retrospectively analyzed survival outcomes of 5 MCL patients diagnosed in our institution between 2004 and 2008. Median age at diagnosis was 64 years (range, 50-74), 4 were male. All had stage IV disease with bone marrow involvement but good performance status (PS 1). Median WBC was 7,380 (range, 5600-11800)/μL. LDH levels were within normal value in 4 patients but one with 1671 IU/L. Three were treated with R-CHOP as initial therapy, 1 with EPOCH-like regimen followed by R-CVEP, 1 with R-HyperCVAD followed by ASCT. Of 2 patients obtaining CR, 1 treated with intensive chemotherapy including ASCT lasted long CR duration. Another patient relapsed within a half year, then received 6 therapies including novel agents such as bendamustine and gemcitabine and is still alive. Although three patients failed to obtain CR, they had received various therapies (range, 3-9) to control disease. One patient died of disease progression with 97.6-month survival duration. As of March 2013, the survival durations of residual patients were 56.1, 61.8, 69.1, and 87.4 months, respectively. [Discussion & Conclusion] The relative long survival duration of our patients might result in either possibility of indolent type or effect of various treatments even without intensive chemotherapy. The individualized clinical management of MCL patients should be further investigated.

前へ戻る